2024年6月25日 · ABBV-951 (foscarbidopa/foslevodopa) is a solution of carbidopa and levodopa prodrugs for 24-hour continuous subcutaneous infusion for the treatment of motor fluctuations …

2024年6月25日 · According to a new announcement, the FDA has again issued a complete response letter (CRL) to AbbVie's new drug application (NDA) for ABBV-951 …

2024年10月24日 · Vyalev (foscarbidopa and foslevodopa) is an approved injectable therapy used to reduce motor fluctuations in people with advanced Parkinson’s disease. Developed by …

2024年10月17日 · According to a new announcement, the FDA has approved AbbVie’s foscarbidopa/foslevodopa, marketed as Vyalev, as the first and only subcutaneous 24-hour …

2023年3月22日 · After submitting the new drug application (NDA) in May 2022, AbbVie has received a complete response letter (CRL) for its investigational 24-hour continuous …

NORTH CHICAGO, Ill., Oct. 17, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved VYALEV™ (foscarbidopa and …

2023年3月22日 · ABBV-951 (foscarbidopa/foslevodopa) is a solution of carbidopa and levodopa prodrugs for continuous subcutaneous delivery that is being investigated for the treatment of …

Foslevodopa-foscarbidopa (also referred to as ABBV-951) is a new soluble formulation of levodopa and carbidopa prodrugs delivered as a 24-h/day continuous subcutaneous infusion …

2024年10月20日 · Previous Name: ABBV-951 Company: AbbVie Inc. Treatment for: Parkinson's Disease. Vyalev (foscarbidopa and foslevodopa) is a carbidopa prodrug and levodopa prodrug …

2022年11月28日 · ABBV-951, a continuous infusion formulation of levodopa/carbidopa that’s administered under the skin, improved “on” time and decreased “off” time when compared with …